Jazz`s ph. 2 essential tremor test misses endpoint
Takeda`s seizure drug fails to meet main goal in late-stage studies
LAS VEGAS, June 3, 2024 /PRNewswire/ -- DelveInsight's Bispecifics/Trispecifics Market Insights report includes a comprehensive understanding of current treatment practices, emerging bispecifics/trispecifics, market share of individual therapies, and current and forecasted market size from 2020 to 2035, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].
ASCO: Jazz shares `unprecedented` biliary tract cancer data
DUBLIN, June 1, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced long-term follow-up results, including the first-ever overall survival (OS) findings, from the Phase 2b HERIZON-BTC-01 clinical trial of zanidatamab in previously treated, unresectable, locally advanced, or metastatic HER2-positive biliary tract cancer (BTC). These data will be featured at the American Society of Clinical Oncology (ASCO) Annual Meeting in a poster presentation during the Gastrointestinal Cancer – Gastroesophageal, Pancreatic, and Hepatobiliary session on June 1, 2024, at 1:30-4:30 p.m. CDT. Zanidatamab is a human epidermal growth factor receptor 2 (HER2)-targeted bispecific antibody being studied in multiple solid tumors.
DUBLIN, May 30, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that thirteen abstracts, including five late-breaking abstracts, featuring new data from across its sleep medicine portfolio will be presented at SLEEP 2024, the 38th annual meeting of the Associated Professional Sleep Societies being held June 1-5, 2024, in Houston, Texas.
DUBLIN, May 29, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review of the Biologics License Application (BLA) for zanidatamab, the human epidermal growth factor receptor 2 (HER2)-targeted bispecific antibody, for the treatment of previously treated, unresectable, locally advanced, or metastatic HER2-positive biliary tract cancer (BTC). Under the Prescription Drug User Fee Act (PDUFA), FDA has set a target action date of November 29, 2024.
DUBLIN, May 29, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Company management will participate in the following investor conferences:
DUBLIN, May 22, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced a strategic collaboration with Life Science Cares to drive social impact through employee volunteerism in the United States. This partnership reinforces Jazz's commitment to supporting the communities in which employees work and live. Life Science Cares is a collective effort to activate the financial and human capital of the life sciences industry across several regions in the U.S. – and partner with nonprofits – to disrupt the cycle of poverty and inequality in those communities. With hubs around Jazz's U.S. offices in Palo Alto, Philadelphia and San Diego, Life Science Cares will help enable Jazz's goals to harness the passion of its employees to make a meaningful difference in their communities.
A pharmaceutical manufacturer known for its sleep medicines will argue Friday before a federal district court that the FDA violated an orphan drug law when it approved a rival product.